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Abstract
The worldwide incidence of kidney failure is on the rise
and treatment is costly; thus, the global burden of illness
is growing. Kidney failure patients require either a kidney
transplant or dialysis to maintain life. This review focuses
on the economics of dialysis. Alternative dialysis modali-
ties are haemodialysis (HD) and peritoneal dialysis (PD).
Important economic factors influencing dialysis modality
selection include financing, reimbursement and resource
availability. In general, where there is little or no facility
or physician reimbursement or payment for PD, the share
of PD is very low. Regarding resource availability, when
centre HD capacity is high, there is an incentive to use
that capacity rather than place patients on home dialysis.
In certain countries, there is interest in revising the reim-
bursement structure to favour home-based therapies, in-
cluding PD and home HD. Modality selection is influenced
by employment status, with an association between being
employedandPDasthemodalitychoice.Costdriversdiffer
for PD and HD. PD is driven mainly by variable costs such
as solutions and tubing, while HD is driven mainly by fixed
costs of facility space and staff. Many cost comparisons of
dialysis modalities have been conducted. A key factor to
consider in reviewing cost comparisons is the perspective
of the analysis because different costs are relevant for dif-
ferentperspectives.Indevelopedcountries,HDisgenerally
more expensive than PD to the payer. Additional research
is needed in the developing world before conclusive state-
ments may be made regarding the relative costs of HD
and PD.
Keywords: cost; economics; haemodialysis; peritoneal
dialysis; reimbursement
Correspondence and offprint requests to: Paul M. Just, Global
Health Economics and Reimbursement, Renal Division, Baxter Health-
care Corporation, 1620 Waukegan Road, MPGR-A2E, McGaw Park,
IL 60085, USA. Tel: +1-847-473-6127; Fax: +1-847-785-6959;
E-mail: paul_just@baxter.com
Introduction
Patientssufferingfromchronickidneydiseasecanbeclassi-
fied according to kidney function along a continuum from
mild renal dysfunction to irreversible kidney failure. Pa-
tients with kidney failure require renal replacement therapy
(RRT), either a kidney transplant or dialysis, to maintain
life. Worldwide, at the end of 2004, ∼1 800 000 patients
were receiving RRT [1]. Of those patients 77% were on
dialysis and 23% were living with a functioning kidney
transplant. The global average prevalence for dialysis was
215 patients per million population, although significant
regional variations existed. By the year 2010, it is ex-
pectedthatthenumberofdialysispatientswillapproachtwo
million [1].
Because the worldwide incidence of kidney failure con-
tinues to rise and treatment is costly, the global burden of
illness is growing. Thus, the resources to be allocated to
RRT are increasing. This review focuses on the economics
ofdialysis.Whilekidneytransplantationhasimportanteco-
nomic implications, it is beyond the scope of this review. A
largevolumeofliteratureexistsonthetopicofkidneytrans-
plantation and its economic impact. Readers are referred to
other review articles for more information [2–4].
For patients treated with dialysis, alternative modalities
are haemodialysis (HD) and peritoneal dialysis (PD). In the
United States, the incidence of HD has increased sevenfold
since 1978, while the incidence of PD peaked in 1995 and
hassincedeclined.In2005,therewereover97000incident
HDpatientsand∼7000incidentPDpatients.Theprevalent
population of HD patients was over 314 000 and the preva-
lent population of PD patients approached 26 000. In other
parts of the world, the utilization of dialysis modalities
varies. Among large nations, the highest utilization of
PD around the world is in Mexico, where it is estimated
that 72% of prevalent dialysis patients were on PD in
2005 (based on data from state of Jalisco). In contrast, in
Luxembourg, no prevalent dialysis patients are reported
to receive PD. Among large nations, PD is used in
[5,6]. Worldwide, at the end of 2004, HD was used to
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treat 89% of dialysis patients while 11% were treated by
PD [1].
Economic factors play a vital role in the sequence of
events that leads to the choice between HD and PD and,
thus, are the starting point for our review. We then ex-
amine the relationship between dialysis modality and em-
ployment status because kidney disease often affects the
working population. We also identify and discuss the costs
of dialysis and key cost drivers for HD and PD, followed
by an overview of the relative costs of dialysis modalities
in different regions of the world.
Economic factors influencing dialysis modality selection
Important economic factors influencing dialysis modality
selection include financing, reimbursement and resource
availability [6,7]. When asked in surveys, physicians re-
spond that financial considerations (i.e. profit status or
facility reimbursement) are not among the primary con-
siderations used in guiding patients to a particular modality
[8–11]. However, literature reveals evidence to the con-
trary. In fact, reimbursement structure has been called ‘the
ultimate controlling force in the establishment and main-
tenance of home dialysis’ [12]. Financial and reimburse-
ment issues have been identified as the most important
non-medical factors in dialysis modality selection in coun-
tries around the globe [6,7,13]. In general, where there is
no facility reimbursement for PD, or where there is little or
no physician reimbursement for PD, utilization is very low
[6,14]. In contrast, in countries with equal or higher reim-
bursement or payment for PD, utilization is much higher.
For example, Mexico is unique in the developing world in
that the utilization of PD is ∼70%. An important reason for
the higher utilization of PD in Mexico is that it has been
the modality with the best financial support from the social
securitysystemandthepublichealthinstitutions[15].Over
the last few years a trend can be observed in a number of
countries to increase the funding of HD services, especially
satellite HD centres, which are smaller and often located
closer to a patient’s home. The recent decrease in utiliza-
tion of PD noted in Mexico may be related to this trend [5].
Additionally, in the growing sector of private-care dialysis,
physicians receive direct payments for HD but not for PD.
In certain countries, there is interest in revising the re-
imbursement structure in a way to provide incentives for
home-based as well as more frequent therapies, including
PD and home HD. In the Canadian province of Ontario,
reimbursement for dialysis changed in 1998. Prior to that
time, reimbursement was based on a fee-for-service sys-
tem, with rates for in-centre HD that were sevenfold higher
than those for home or community-based HD or PD. After
1998, a modality-independent weekly capitation fee was
adopted. This change in reimbursement structure arguably
contributed to a stabilization of an ongoing reduced utiliza-
tion of PD and non-hospital-based HD in Ontario, while
the utilization of PD continued to decline in other parts of
Canada [16]. In Hong Kong, the government long ago re-
moved the upper age limit of 55 years for subsidizing home
dialysisconsumablesandcontinueswitha‘PDFirst’policy
[7].InJapan,reimbursementforHDisbeingdecreased,and
the Japanese Ministry of Health and Welfare is promoting
home healthcare. A similar situation is present in Taiwan
where theBureau ofNational Health Insurance (BNHI)has
reduced points for HD but maintained those for PD in an
effort to increase PD utilization.
Historically, home dialysis was more common in the
UnitedKingdom(UK)thanitistoday.Thishadbeenrelated
to resource constraints and reduced access to HD services
in some communities. Thus, a stimulus for preferential use
ofhomecontinuousambulatoryperitonealdialysis(CAPD)
had existed, as access to HD services was limited in some
regions. Renal clinicians were able to transfer a significant
portion of the resource responsibility for CAPD patients
to general practitioners who could, at that time, prescribe
CAPD therapy. However, since April 1995, general practi-
tioners have not been permitted to prescribe CAPD fluids
[17]. More significantly, over the last several years, follow-
ing publication in 2002 of a National Institute for Clinical
Excellence (NICE) guideline [18], there has been a signif-
icant expansion of access to HD services as a result of a
capital development programme in which £60 million were
to be invested between 2000 and 2006 by the government
for expansion of access to, in particular, satellite HD ser-
vices. During this period, a National Service Framework
was published to define standards of dialysis care and es-
tablish good practice markers and support balanced access
to all dialysis modalities in England [19].
Medicare policy in the United States provides incentives
to private insurers, dialysis facilities, patients and physi-
ciansforhomedialysisoptions.Theseincludewaiverofthe
90-day Medicare coverage waiting period, additional add-
ons to the capitated, or composite, rate for home training,
home training supervision fees for physicians, the avail-
ability of a training exception rate and an alternative reim-
bursement option referred to as Method II reimbursement
[20].UnlikepatientsusingthemuchmorecommonMethod
I reimbursement, Method II patients do not receive their
home supplies and equipment from their dialysis provider
directly. Rather, they receive them from an independent
supplier who bills Medicare for actual supplies used on a
reasonable charge basis using local prevailing rates up to a
capitated maximum that varies by modality. More recently,
the Centers for Medicare and Medicaid Services (CMS)
modified the physician monthly capitated payment system
to improve care quality in a manner that they believe pro-
vides an incentive for home dialysis therapy. Physicians are
requiredtopersonallyevaluatein-centreHDpatientsatleast
once each month but receive payment based on three tiers
of patient contact, one visit, two or three visits or four visits
per month. They may use physician extenders, such as a
physician’s assistant, clinical nurse specialist or nurse prac-
titioner, to evaluate patients for the second through fourth
visits. CMS believes that the incentive for home dialysis
is provided by not requiring a monthly evaluation visit for
homepatients,notspecifyingarequiredvisitfrequencyand
fixingthephysicianpaymentrateforhomedialysispatients
at∼2%belowtheratepaidfortwotothreeevaluationvisits
for in-centre HD patients [21].
Unfortunately, evidence published both prior to and after
implementation of this policy does not support the sup-
position that increased dialysis patient visit frequency re-
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implementationofthenewpolicy,Plantingaandcolleagues
reported results of a prospective cohort study that found
that the frequency of patient–physician contact was not
associated with improvements in patient survival, hospi-
talization rate, quality-of-life or patient-rated care [22].
Following implementation of the new policy, Mentari and
associates compared outcomes in over 2000 patients be-
tween 12 months prior to implementation of the policy
to 7 months after implementation. Despite a doubling of
patient–physician contact, from 1.52 before to 3.14 vis-
its per month after policy implementation, they found no
associated change in hospital admissions or days, quality-
of-life, patient satisfaction or numerous markers of quality
outcomes [23]. Anecdotally, some suggest that the lower
maximum monthly reimbursement opportunity for physi-
cians caring for home dialysis patients compared to in-
centre HD patients does not align with published evidence
suggesting that patients receiving home dialysis, either PD
or HD, have superior outcomes as measured by survival,
quality-of-life and patient satisfaction.
Resource availability also influences dialysis modality
selection [6]. When centre HD capacity is high, there is a
strong incentive to use the capacity rather than place the
patient on an alternative dialysis therapy that does not use
it. More recent approaches that lease or place the HD hard-
wareandsellthesuppliesatapremium,thusintegratingthe
hardware cost into the supply cost, are increasingly com-
mon. Such an approach may be noted in environments with
distinctly separate budgets for capital investment and sup-
plies or therapy management services and in which there
arespecificconstraintsonexpandedcapitalinvestment.The
inverse may also be found. Finally, a current trend noted in
many parts of the world is the growth of satellite HD cen-
tres. These centres are often self-care or limited care and
aremostfrequentlysmallunitsbuiltinconvenientlocations
closer to patient homes to allow easier access to HD.
Dialysis modality and employment status
Theimpactofrenalinsufficiencyonworkplaceproductivity
is substantial. There is a significant reduction in workforce
participation among patients with renal dysfunction aged
18–64 years. A conservative estimate of lost productiv-
ity from workforce non-participation associated with renal
dysfunction in 1994 was ∼$665 million [25].
A number of cross-sectional analyses have examined the
relationshipbetweendialysismodalityandemploymentsta-
tus. Most studies have found that PD patients are more
likely to be employed than HD patients. However, because
of the cross-sectional nature of the research, it is difficult
to conclude whether dialysis modality influenced employ-
mentstatus,orwhetheremploymentstatushadaninfluence
on the choice of dialysis modality [26–29].
Two studies address the limitations of these cross-
sectionalanalyses.Amulti-centre,prospectivestudyinThe
Netherlands followed 359 patients for 12 months. No rela-
tionship between treatment modality (HD or PD) and em-
ployment status was observed. The authors concluded that
many patients become unemployed before starting dial-
ysis. They also concluded that most patients who have
a job at the start of dialysis keep working. Finally, the
authors suggested that treatment modality does not influ-
ence the ability to maintain employment, but employment
may influence the choice between HD and PD [30].
Another study utilized a simultaneous probit model to
account for the potential endogeneity between treatment
choice and employment [31]. Data were analysed from
Wave II of the United States Renal Data System’s Dial-
ysis Morbidity and Mortality Study. The authors concluded
that PD has a causal effect on dialysis patients’ ability to
participate in the labour force; however, the magnitude of
the effect is small in absolute terms and much smaller than
the effect implied by previous cross-sectional research, in
which endogeneity was ignored. In a naive model ignor-
ing endogeneity, PD patients were ∼60% more likely to
be employed than HD patients; however, in a two-stage
model accounting for endogeneity, the relative increase in
the probability of working for PD patients compared to HD
patients was only 14.7%. The authors further stated that
most of the effect of PD on employment arises from en-
dogenous selection of PD by patients who wish to maintain
employment,ratherthanfromtheabilityofPDtoeasework
scheduling [31].
Asummaryoftheliteraturereferencedaboveisprovided
in Table 1.
The costs of dialysis
Recent analyses in the United States have reported the
Medicarepaymentstocompensateforayear’streatmentofa
dialysispatienttobeabout$67000.Employergrouphealth
insurance payment is much higher at $180 000 per year.
Medicare expenditures for end-stage renal disease (ESRD)
claims increased 11.2% in 2004, to ∼$19 billion. Employer
group health plan expenditures for ESRD increased to
$390 million in 2004, representing a 56% increase com-
pared to the previous year [5]. In Europe, although dialysis
patients make up [32]. From 1990 to 2010, treatment costs
fortheglobal maintenance dialysispopulation areexpected
to rise from [33].
The costs of dialysis around the world can vary widely
according to many local market conditions, including local
production and distribution factors, import duties, the pres-
ence or absence of local suppliers and purchasing power.
HD cost is driven largely by the fixed costs of facility space
and staff. HD machines typically cost ∼$18 000 to $30 000
each, but the machines have a 5- to 10-year life cycle, and,
in a weekly schedule, three to six patients can be treated
on one machine. The cost of dialyzers for HD ranges from
$1000 to $5000 per year. Other items that factor into the
costofHDareadditionalfacilitycostssuchasmaintenance
and utilities, and the costs of transportation to and from the
HD facility [26].
In contrast, the economics of PD are driven primarily by
variable,or‘disposable’,costs,suchasthecostsofsolutions
and dialysis tubing, and PD exhibits a near constant econ-
omy of scale [26,34]. A review of the literature determined
that the cost of PD materials ranges from $5000 to $25 000
annually. The use of automated cyclers generally adds to
the cost of PD. The machines cost $3000 to $10 000 each
when purchased outright. However, they may be leased or2368 P. M. Just et al.
Table 1. Dialysis modality and employment status
Reference Baseline
employment (%)
Time on dialysis On dialysis
employment (%)
Statistical significance
HD PD HD PD
Rubin et al. [28] – – 7 weeks 11.3 28.1 P < 0.001
Blake et al. [26] – – >3 months 41 43 NS
Wolcott and Nissenson [29] – – >6 months 12a 45a Not reported
Julius et al. [27] – – Not available 9.6 27.4 P < 0.05
van Manen et al. [30] 31 48 1 year 25 40 NSb
Hirth et al. [31] – – 60 days 32.2c 51.3c P < 0.01
Hirth et al. [31] – – 60 days 40.6d 46.6d P < 0.01
aIncludes patients currently employed or in school or who routinely perform household tasks.
bNo association between treatment modality and loss of employment when adjusted for demographic, clinical variables and SF-36 summary scores.
cRelative probability of employment when dialysis modality is treated as an exogenous variable in a model that does not account for endogeneity.
dRelative probability of employment when dialysis modality is treated as an exogenous variable in a model that accounts for endogeneity.
provided, in which case their actual cost is bundled into the
cost of solutions and materials purchased through the same
company. Comparison of supply costs alone may result in
inaccurate assessment of the absolute cost of the various
dialysis therapies.
That said, supply-related issues do impact provider costs
of both dialysis modalities. For HD, provider costs can be
affected by the choice of the dialyzer membrane prescribed
and whether or not the dialyzer is used only one time or
is reused. A key issue influencing the apparent daily cost
of PD is that some new dialysate solutions are priced at a
premium relative to the standard glucose solutions. When
comparing dialysis treatment costs on a procurement basis
only, misleading conclusions may be reached. For exam-
ple, when one standard bag of dialysate is replaced with the
newersolutionicodextrin,thenetdailycostforthatpatient’s
dialysis treatment might appear to increase in some coun-
tries. However, such an increase in daily therapy cost may
bemorethanoffsetifthealternativewouldhavebeentrans-
ferandmaintenancetoamoreexpensivedialysistreatment,
such as HD, as documented later inthis manuscript. Budget
impactmodelsandMarkovanalysishavereportedthatsuch
extension of time on PD therapy lowers the total costs of
care over time by deferring the need for HD, which is gen-
erally found to be a more expensive treatment alternative
[26,35,36]. Such analyses underscore the need to evaluate
dialysis treatment costs as a total therapy rather than simply
thinking of dialysis costs as the procurement expense of
the supplies. Additionally, this example demonstrates the
value of considering the cumulative costs of dialysis over a
patient’s therapy lifetime rather than for a limited discrete
segment of time.
Additional costs associated with dialysis are physician
fees, medications, laboratory and other diagnostic inves-
tigations and hospitalizations. For example, in the United
States in 2004, Medicare spending for erythropoiesis stim-
ulating agents was ∼10% of total Medicare spending for
all ESRD care services [5]. Medication costs with PD are
typically less than those with HD. Less erythropoietin is
required because anaemia is less severe. More inexpensive
forms of Vitamin D tend to be used (oral or subcutaneous
versus intravenous), and less parental iron is required be-
causepatientsarelesslikelytohavetreatment-relatedblood
losses [26].
Hospitalization costs contribute substantially to total ex-
penditures for dialysis patients [26]. Room costs and in-
patient dialysis costs account for nearly half of the cost of
hospitalizations for dialysis patients. Some evidence sug-
gests that hospitalization costs are lower for PD than for
HD due to a reduced number of hospital days per year
[37,38]; however, a comprehensive literature review indi-
cates that hospitalization costs are similar for HD and PD,
although the reasons for hospital admission differ. The pri-
mary causes of hospital admission in patients receiving PD
are peritonitis and cardiovascular disease [39–44]. Con-
versely, in patients receiving HD, the primary causes for
hospitalization are access issues, thrombosis and infections
[26].Ratesanddurationofhospitalizationbymodalitymay
vary in different regions of the world, so caution should be
used in generalizing research results.
The cost of treating patients with chronic kidney dis-
ease who ultimately progress to ESRD begins to increase
in the last 6 months immediately prior to starting dialysis,
peaks in the first month of dialysis, and generally reaches
a plateau by Month 6 of dialysis. One reason for this is that
mortality is high during the first 6 months of dialysis, and
patient treatment is more expensive in the period immedi-
ately prior to a terminal event [5,45]. Also, start-up costs
occur with all dialysis modalities and result in higher costs
for the first year of dialysis compared to subsequent years.
Start-up costs include surgical implantation of an access.
A peritoneal catheter must be inserted for PD and a vas-
cular access, fistula, graft or temporary catheter must be
established for HD. Finally, start-up costs for CAPD and
home HD include patient training and so also contribute
to the cost of modality switches because they are incurred
with each change in modality [46]. When considering a pa-
tient lifetime approach, it has been shown that total payer
expense over a 3-year period is lowest when patients are
started on PD and maintained on it for at least Year 1 of the
3-year period [47].
A key factor influencing the cost of dialysis care is the
timingofreferraltoanephrologist.Whenpatientsareeither
referredlatetoanephrologist’scareormusturgentlyinitiate
dialysis without a planned access, they are generally sicker,
require longer hospitalization and are nearly always started
onHD.Earlyreferralandplannedstartresultincostsavings
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to a nephrologist have an extended time prior to starting
RRT during which access may be planned and placed, and
patients may be objectively educated about their treatment
choices. This approach has usually been found to result in
fewer inpatient hospital days [48]. Patients who have been
exposed to pre-dialysis modality education are more likely
to choose PD over HD [49–51] and therefore contribute to
lower societal and payer dialysis expense in most countries,
as discussed below.
Economic evaluations of dialysis treatment
modalities
ThegrowingkidneyfailurepopulationandhighcostofRRT
have led to early economic evaluations of the medical tech-
nology. Some propose that few other medical technologies
havehadtheircostsandoutcomesassessedsoregularlyand
widely [4]. However, the research varies greatly in quality.
One factor to consider in reviewing the economic assess-
ments of dialysis modalities is the perspective taken for the
analysis. Relevant perspectives include: patient, dialysis fa-
cility or provider, physician, payer, dialysis manufacturing
industry, government and society as a whole. The costs to
payers, facilities and physicians are most likely to affect
practice patterns such as modality selection. Costs to so-
ciety and patients or families are less likely to influence
practices [26]. Depending on the perspective of the analy-
sis, different costs or expenses may be relevant. A previous
analysis found that many dialysis economic evaluations fail
to include costs that are relevant for the stated perspective
[52].
Costs are generally described in four categories: direct
medical costs, direct non-medical costs, indirect costs and
intangible costs. Direct medical costs of dialysis include
staffing costs, physician fees or salary, costs of dialyzers
and tubing in HD, costs of solutions and tubing in PD, costs
associatedwithradiology,laboratoryandmedications,cap-
ital costs of HD machines and PD cyclers, costs of hospi-
talizations and costs of outpatient consultations from other
specialties [26].
Direct non-medical costs may vary widely in different
parts of the world but tend to be highest in more devel-
oped economies. Direct non-medical costs include build-
ing costs, facility utilities and other overhead costs. These
costs are difficult to estimate but are important elements
of an economic evaluation of dialysis modalities. Addition-
ally, an activity-based cost analysis is the most appropriate
cost approach to apply when comparing modality expenses
between home and centre-based therapies. Activity-based
cost analysis apportions costs according to the propor-
tional share of a particular cost element used by patients
on different modalities. However, in practice it appears that
this method is not applied by a number of dialysis centre
managers.
Intangible costs are the costs associated with pain, suf-
fering and impairment in quality of life (QOL), as well
as the value of extending life. These costs are often omit-
ted from economic evaluations. Likewise, indirect costs, or
productivity losses for patients and their families or care-
takers, rarely have been assessed and incorporated in dial-
ysis economic evaluations. While it is true that the mean
age of the kidney failure population is increasing and that
many patients are past the age of retirement when they
start dialysis, indirect costs still represent a potentially
important element of dialysis economic evaluations [26].
This is particularly true in health systems are dependent
uponemployeeandemployercontributionstofundmedical
care. When patients do not continue to work, both sources
of contribution cease. Additionally, such a social system
generally will pay a disability income to non-working
patients in addition to their medical care payment or
reimbursement.
The majority of studies that compare dialysis modalities
have focused solely on costs, rather than cost-effectiveness
or cost-utility [26,52]. In part, this may be because survival
and QOL outcomes for HD and PD are generally consid-
ered to be similar [26]. However, without large, random-
ized, prospective clinical trials comparing patient survival
and other outcomes between the various dialysis modal-
ities, quality cost-effectiveness or cost-utility evaluations
are not possible. In the clinical literature, a number of ob-
servationalstudiesprovideconflictingsurvivalresults,with
some demonstrating a survival advantage for HD [53–55],
othersfinding asurvival advantage forPD[56–59] andstill
others showing equal or mixed survival outcomes between
modalities [60–62]. To a great extent, these disparate find-
ings are explained by differences in study methods. When
evaluated according to modern evaluation and statistical
standards, only comparisons of incident patients are appro-
priate and adjustments must be applied for comorbid con-
ditions. The most recent survival assessments of patients
from four of the world’s leading dialysis registries, Canada,
Denmark, the Netherlands and the United States, find that
overall survival is similar between the modalities but that
there may be differences in select patient subgroups [63].
In the QOL literature, most research indicates that PD
and HD patients have similar QOL, regardless of whether
QOL is measured by a generic or disease specific measure
or whether it is measured by a health profile or health
preference instrument [64–67]. However, some evidence
suggests that PD may offer an advantage in QOL over HD
[68–71], while other research has found that HD may be
superiortoPDincertainQOLdomains[71,72].Differences
in patient characteristics and research methods may explain
some of these conflicting results.
A North American literature review concluded that PD
is less expensive than HD and that the difference in cost is
dramatic when the PD program is relatively large and well
run.AnnualcostsforHDpatientsrangedfrom∼$48000to
∼$69 000, while annual costs for PD patients ranged from
∼$34 000 to ∼$47 000. The cost ratio of HD to PD varied
from 1.22 to 1.52 [26].
Ingeneral,reportsfromWesternEuropeareinagreement
withtheNorthAmericanfindings.Areviewoftheliterature
found that in-centre HD was about twice the cost of CAPD
in France and 30% more expensive than CAPD in Italy
and the UK [26]. Another review of the Western European
literature also concluded that, with the exception of home
HD, PD is less costly than HD. However, that review noted
that the magnitude of the cost difference between dialysis2370 P. M. Just et al.
modalities is difficult to determine due to deficiencies in
theavailableevidence.Manypublicationsfailtoadequately
describe their methodology or to include all relevant cost
components [52].
Very little research exists on the economics of dialysis
in developed Asian countries. A multi-national survey of
Asian nephrologists conducted in 2001 suggests that HD is
generally more expensive than PD in the developed Asian
countries of Hong Kong, Singapore, Taiwan and Japan.
However, the extent of cost savings with PD varies by re-
gion. According to the survey results, the ratio of costs for
HD compared to PD ranged from a low of 0.99–1.09 in
Japan to a high of 1.42–2.39 in Hong Kong [73].
The economics of dialysis in the developing world dif-
fer from advanced nations. CAPD requires less technol-
ogy than HD, so it would seem particularly well suited for
developing nations [15,74]. In poorer countries, though,
labour is relatively inexpensive, while the cost of imported
equipment and solutions is high. Costs are often consid-
ered as related only to supplies rather than assessed as a
total therapy. Therefore, there is often a perception that
PD is more expensive than HD in developing countries
[26,75]. To reduce costs, patients may be placed on out-
datedstraight-linesystemsandsometimestransfersetsmay
be reused. However, high peritonitis rates increase the cost
of PD treatment even further, and dropout rates are high
[15,74]. The lack of well-conducted economic evaluations
in developing countries makes it difficult to accurately un-
derstand the true economic environment for dialysis care.
A systematic review of the world literature on reports
of dialysis economics and cost-effectiveness was recently
published [76].
Comments
Kidney failure is a disease with high resource demands on
every health care system in the world. The literature sup-
portsaperceptionthatthedrivingforcesofpatientmodality
selection are intricately linked to payment and reimburse-
ment mechanisms in any society. As such, it is critical that
any analysis of economics related to dialysis therapy must
start with a clear understanding of the perspective from
which the analysis is conducted and, therefore, interpreted.
Allrelevantcostsforagivenperspectivemustbeincludedin
the analysis whenever possible, and may include expenses
both directly and indirectly related to the provision of the
dialysisservice.Examplesincludefacility,hardware(dialy-
sismachineandwatertreatment),medicalandnon-medical
personnel, hospitalization and complication management,
accesscreationandmanagement,disposablematerial,phar-
maceutical, diagnostic, transportation and social costs. Ad-
ditionally, indirect costs and intangible costs may have a
greater contribution in some countries.
There are many complex and interrelated direct flows
of money between participants in the care chain, includ-
ing the patient, the physician, the provider of the dialysis
service and any hospital facility supporting the patient’s
extended care needs plus health care product suppliers
and medical distributors. Indirectly, kidney failure causes a
societal burden in that patients otherwise able to work and
contribute to society become disabled, thus reducing so-
cietal tax income and increasing disability disbursements
once working-age patients are no longer able to continue
working. The impact of kidney failure on workplace pro-
ductivity is substantial, with many patients becoming un-
employed even before starting dialysis. Patients who are
employed have a greater tendency to select PD rather than
HD; however, the choice of dialysis modality has not been
proventoindependentlyaffectapatient’sabilitytomaintain
employment.
When considered from the perspective of society or a
payer, such as a health care funding authority or a principal
insurer,theresourcedemandsofakidneyfailurepatientare
best considered over the course of that patient’s cumulative
remaining lifetime. Consideration of the cost-effectiveness
of equivalent treatment alternatives as measured by effec-
tiveness, safety and quality may then be balanced with their
respective budget impact to the primary payers. A lower
cost treatment alternative will extend available resources to
allow improved treatment for more patients and will lower
the lifetime treatment cost burden of an individual patient
and the diseased population to society. In practical terms,
this suggests that home dialysis alternatives should be pref-
erentially selected when clinically and socially appropriate
for the individual patient. Such an approach has been advo-
cated [13] and the funding benefits have been documented
using an analysis of US Medicare data [47].
Unfortunately, in a majority of health care systems, this
approach is not followed, particularly in the case of private-
care services [7,32]. From the perspective of society, health
care should be aligned for greatest efficiency as measured
bytheabilitytoprovidethehighestqualitycaretothelargest
number of patients. When a treatment is equally effective
and safe for patients, yet least costly to the principal payer,
incentives that drive downstream care decision makers and
providers topreferentiallyselectthatsametherapytobethe
initial treatment option are prudent.
Appropriate alignment of incentives throughout the
downstreamcaresystemmaynotoccurbecausecostdrivers
for PD and HD differ; PD is driven primarily by variable
costs while HD is driven more by fixed costs. In devel-
oped nations, HD is generally more expensive than PD to
the payer. In some developing and emerging economies,
mainly due to inexpensive labour and high imported equip-
ment and solution costs, PD is perceived to be more expen-
sive than HD despite the lack of confirmatory prospective
economic evaluations. However, the costs of dialysis differ
by region and additional research is needed, particularly in
the developing world.
Conclusions
When reviewing dialysis economic evaluations, key factors
that significantly influence their interpretation include the
perspective taken for the analysis and the cost components
included in the comparison. All relevant costs for a given
perspective must be included whenever possible. These in-
clude expenses both directly and indirectly related to the
provision of the dialysis service as previously described.Reimbursement and economic factors influencing dialysis modality choice 2371
Additionally, indirect costs and intangible costs may have
a more or less significant contribution to economic evalua-
tions in different economies.
In most regions of the world, an analysis of total therapy
expenses reveals that home dialysis is a lower cost option
than in-centre dialysis and PD is a lower cost modality
than HD, particularly when comparing CAPD to in-centre
HD. The actual cost of each modality may be affected by
supply expenses, such as dialyzers for HD and solutions
for PD, but the absolute impact of such elements can only
be discovered by economic analysis that would concur-
rently evaluate the influence of those supply factors on
overall patient outcomes. Unfortunately, cost-effectiveness
and cost-utility studies based on randomized prospective
clinical trials comparing home to in-centre dialysis modal-
ities are unavailable and are unlikely to take place, as
most patients do not wish to leave their modality choice to
chance.
As health systems continue to shrink, in even developed
countries, resource intensive therapies such as treatments
for patients with kidney failure will need to find new ef-
ficiencies. Renal transplantation, while the most clinically
and financially effective approach for kidney failure pa-
tients [77], is unlikely to become significantly more avail-
able in the near future in most countries.
Healthcare systems have historically supported resource
intensive treatments because the previously more common
fee-for-service approach rewarded utilization of expensive
services such as dialysis in general and HD in particular.
Today, the approach to healthcare reimbursement is chang-
inginmanypartsoftheworldtoeitheracapitatedsystemor
one using a global budget. As these become more routine,
incentives should be optimized to better support efficient
treatment option alignment. When dialysis modalities are
selected, economic factors such as financing, reimburse-
ment and resource availability do not appear to be wholly
independentfromclinicalconsiderationswhenmodalityse-
lection recommendations are discussed with patients. The
rate of PD utilization appears to be positively associated
with equal or higher reimbursement or payment for PD.
When centre HD capacity is high, there is a perceived and
actual incentive to utilize that capacity, rather than to place
patients on alternative modalities such as a home dialysis
treatment option.
Further research is needed to allow direct comparison
of the complete expenses of the various dialysis modalities
appliedinagivenregion.Combinedwithapopulationrisk-
factor-adjusted prospective selection of the best outcome
modality treatment and practice alternatives, future dialysis
resources application may become more efficient.
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